Sarepta Therapeutics
SRPT
#4817
Rank
ยฃ1.44 B
Marketcap
ยฃ13.81
Share price
1.14%
Change (1 day)
-83.78%
Change (1 year)
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.

P/S ratio for Sarepta Therapeutics (SRPT)

P/S ratio as of February 2026 (TTM): 0.8071

According to Sarepta Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.48. At the end of 2025 the company had a P/S ratio of 0.7962.

P/S ratio history for Sarepta Therapeutics from 2001 to 2025

PS ratio at the end of each year

Year P/S ratio Change
20250.7962-86.95%
20246.10-15.9%
20237.26-40.49%
202212.29.13%
202111.2-55.15%
202024.9-2.22%
201925.5-1.12%
201825.810.75%
201723.3-91.58%
2016276-80.34%
2015> 10002193.16%
201461.313.28%
201354.1146.82%
201221.9918.16%
20112.15-73.42%
20108.10-11.73%
20099.17316.41%
20082.20-73.37%
20078.27-99.44%
2006> 10003874.02%
200536.9-81.29%
200419736.42%
2003145-8.87%
2002159-55.81%
2001359

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Gilead Sciences
GILD
6.45 698.72%๐Ÿ‡บ๐Ÿ‡ธ USA
PTC Therapeutics
PTCT
3.15 290.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
1.46 81.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
14.0 1,637.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Insmed
INSM
76.8 9,417.70%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
3.09 283.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Avidity Biosciences
RNA
539 66,730.64%๐Ÿ‡บ๐Ÿ‡ธ USA